Mutagenicity of antineoplastic drug residues treated in health care waste autoclave

Bulletin of Environmental Contamination and Toxicology

Volumn 71, Issue 1, 2003, Pages 170-175

  Bassi, M D ^a   Moretton, J ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ARGENTINA; ARTICLE; ENVIRONMENTAL EXPOSURE; GENOTOXICITY; HAZARDOUS WASTE; HEALTH HAZARD; HOSPITAL WASTE; MUTAGENICITY; NONHUMAN; SALMONELLA TYPHIMURIUM; WASTE DISPOSAL;

ANTINEOPLASTIC AGENTS; DRUG RESIDUES; HEAT; MEDICAL WASTE; MEDICAL WASTE DISPOSAL; MUTAGENICITY TESTS; MUTAGENS; SALMONELLA; STERILIZATION;

SALMONELLA TYPHIMURIUM;

EID: 0038016522     PISSN: 00074861     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00128-003-0145-7     Document Type: Article

References (16)

1. ASHP (1985) ASHP technical assistance bulletin on handling cytotoxic drugs in Hospitals. American J Hosp Pharm 42: 131-137
2. Benedict WF, Baker MS, Haroun L, Chol E, Ames BN (1997) Mutagenicity of cancer chemoterapeutic agents in the Salmonella/microsome test. Cancer Res 37: 2209-2213
3. Brooke D, Scott JA, Bequette RJ (1975) Effect of briefly heating cyclophosphamide solutions. American J Hosp Pharm 32: 44-45
4. Castegnaro M, Adams J, Armour MA, Barek J, Benvenuto J, Confalonieri C, Goff U, Ludeman S, Reed D, Sansone EB, Telling G (1985) Laboratory decontamination and destruction of carcinogens in laboratory wastes: some antineoplastic agents. IARC Scientific Publication N° 73. IARC, Lyon
5. Connor TH, Anderson RW, Sessink PJM, Broadfield I, Power LA (1999) Surface contamination with antineoplastic agents in six cancer treatment centers in the United States and Canada. American J Health-Syst Pharm 56: 1427-1432
6. EPA (1994) Technical assistance manual: state regulatory oversight of medical waste treatment technologies. U. S. EPA, Atlanta, Georgia
7. Ferguson LR, Pearson AE (1996) The clinical use of mutagenic anticancer drugs. Mut Res 355: 1-12
8. Friedman OM, Bien S, Chakrabarti JK (1965) Studies on the hydroysis of cyclophosphamide. Identification of N-(2-hydroxyethyl)-N′-(3-hydroxypropyl) ethylendiamine as the main product. J American Chem Soc 87: 4978-4979
9. Hessel H, Radon K, Pethran A, Maisch B, Gröbmair S, Sautter I, Fruhman G (2001) The genotoxic risk of hospital, pharmacy and medical personnel occupationally exposed to cytostatic drugs-evaluation by the micronucleus assay. Mut Res 497: 101-109
10. Kummerer K, Helmers E (1997) Hospital effluents as a source for platinum in the environment. Sci Total Environ 193: 179-184
11. Maron DM, Ames BN (1983) Revised methods for the Samonella mutagenicity assay. Mut Res 113: 173-215
12. Masaharu H, Hirotane K, Masaya B (1967) Cyclophosphamide. I Determination and degradation kinetics in aqueus media. Shionogi Kenkgusho Nempo 17: 107-113
13. Mortelmans K, Zeiger E (2000), The Ames Salmonella/microsome mutagenicity assay. Mut Res 455: 29-60
14. Pruess A, Giroult E, Rushbrook P (1998) Safe management of wastes from health care activities. WHO, Geneva
15. Sessink PJM, Boer KA, Scheefhals APH, Anzion RBM (1992) Occupational exposure to antineoplastic agents at several departaments in a hospital. Int Arch Occup Environ Health 64: 339-342
16. Sorsa M, Hemminki K, Vainio H (1985) Occupational exposure to anticancer drugs-Potential and real hazards. Mut Res 154: 135-149